Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance

Ji, Hongyan; Chen, Li; Dai, Yunpeng; Sun, Xutong; Li, Xiuli; Wang, Qi; Ma, Daoxin; Du, Dongdong; Zhao, Ping; Wang, Yulin

doi:10.3892/ol.2017.6981

Cited by 9 publications

(16 citation statements)

References 39 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, our result of CD133 expression agrees with Fetnat M. Tolba and his colleague who reported no correlations were elicited between CD133 expression and ALL [16] , but disagreed with other studies that found strong expression of CD 133 in ALL [17] . These differences may be due to the detection of mRNA expression in their studies rather than flow cytometer.…”

Section: Discussioncontrasting

confidence: 83%

Significance Aberrant Of CD133 Expression and Their Clinical Impact in Acute Lymphoblastic Leukemia among Sudanese Patients in Khartoum State

Atia

Hamid

Elkarsany

et al. 2021

ijirms

View full text Add to dashboard Cite

Background: Acute lymphoblastic leukemia (ALL) is a malignant disease that arises from several genetic mutations in a single B- or T-lymphoid precursor, resulting in altered blast cell survival, proliferation, and maturation. Objectives: This current study was aimed to determine the significance of aberrant CD133 and 45 expressions in Sudanese Patients with Acute lymphoblastic Leukemia, and their clinical significance in Khartoum state. Materials and Methods: One hundred Sudanese participants were enrolled in this study as follows: 88 Patients diagnosed with ALL as a case and 12 healthy controls donors were randomly selected. 2.5-5 mL of EDTA blood/bone marrow for flowcytometry from each patient and controls subject. Results: Eighty-eight newly diagnosed Sudanese patients with acute lymphocytic leukemia (ALL) were involved in this study, their age average is (15.7) and their stander deviation (SD) is 17.4. The frequency of aberrant markers concerning control groups was significantly associated with all patients in CD 45 with a P value (0.0001), while there was no difference between cases and control in the frequency of CD 133 antigen, there was no significant difference between age groups in the expression of different aberrant antigens. The study was significantly more expressed CD133 in males than females. Also no significant difference in hematological parameters between patients with or without expression of Aberrant CD 45 and 133 markers, while we found significantly high TWBCs in T. cell leukemia. Conclusion: Aberrant myeloid antigens CD45 was significantly associated with childhood and adult ALL and may be considered as important prognostic factors, while CD 133 were not associated with ALL.

show abstract

Section: Discussioncontrasting

confidence: 83%

Significance Aberrant Of CD133 Expression and Their Clinical Impact in Acute Lymphoblastic Leukemia among Sudanese Patients in Khartoum State

Atia

Hamid

Elkarsany

et al. 2021

ijirms

View full text Add to dashboard Cite

show abstract

“…7 In our previous study, frequencies of CD34+CD82+ cells in childhood ALL were higher than those in controls. 8 Furthermore, aberrant expression of CD82 in CD34+CD38− LSCs was detected by comparing the protein expression profile of CD34+/CD38− LSCs freshly isolated from individuals with AML to that of their CD34+/CD38+ counterparts. 9 Importantly, it was revealed that CD82DR in CD34 +CD38− AML cells could inhibit the colony-forming ability of these cells.…”

Section: Discussionmentioning

confidence: 99%

“…In hematopoietic malignancies, it was reported that CD82 is highly expressed in leukemia cells from patients with human leukemias, including AML. 7 In the previous study, 8 it has been found that CD82 was highly expressed in pediatric patients with ALL. In a methylcellulose medium, CD82 levels are correlated with the colony-forming abilities in CD34 +/CD38− AML cells 9 whose cells fulfilled the criteria for LSCs in vivo.…”

Section: Introductionmentioning

confidence: 88%

CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/β-catenin signaling pathway

Chen

Xing

et al. 2019

Pediatr Res

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Stem cell marker CD82 plays a vital role in the oncogenesis and progression of acute myelogenous leukemia (AML), especially in sharing properties of leukemia stem cells (LSCs). The Wnt/β-catenin pathway is required for the development of LSCs in AML. The present study aimed to validate whether CD82 supports the survival of LSCs in pediatric AML via activation of Wnt/βcatenin signaling pathway. METHODS: CD82 expression and its correlation with molecules downstream of Wnt/β-catenin pathway in samples from pediatric AML patients were analyzed. Forced or downregulated expression of CD82 in AML cells was evaluated for the effects of CD82 on cell proliferation, cycle regulation, apoptosis, and adriamycin chemoresistance and to validate the underlying mechanism. RESULT: Aberrant expression of CD82 in pediatric AML patients was found. CD82 messenger RNA expression correlated positively with downstream molecules of Wnt/β-catenin pathway in AML children. Knockdown of CD82 induced apoptosis, suppressed growth, and decreased adriamycin chemoresistance in AML cells. CD82 accelerated β-catenin nuclear location and then stimulated the expression of downstream molecules of Wnt/β-catenin pathway. CONCLUSION: CD82 regulates the proliferation and chemotherapy resistance of AML cells via activation of the Wnt/β-catenin pathway, which suggest that the CD82 may be a potential therapeutic target in AML children.

show abstract

“…The association between tetraspanin expression and cancer prognostic is found in many kinds of cancers (Table 1 ). In B lymphoma, aberrant expression of CD9, CD81, and CD82 was linked to B-acute lymphoblastic leukemia ( 30 – 32 ). Increased CD37 expression was found in B cell malignancies and thus CD37 antibodies were developed to deplete malignant B cells for the treatment of chronic lymphocytic leukemia ( 33 ).…”

Section: Functions Of Tetraspanins In B Cellsmentioning

confidence: 99%

Expression and Function of Tetraspanins and Their Interacting Partners in B Cells

et al. 2018

View full text Add to dashboard Cite

Tetraspanins are transmembrane proteins that modulate multiple diverse biological processes, including signal transduction, cell–cell communication, immunoregulation, tumorigenesis, cell adhesion, migration, and growth and differentiation. Here, we provide a systematic review of the involvement of tetraspanins and their partners in the regulation and function of B cells, including mechanisms associated with antigen presentation, antibody production, cytokine secretion, co-stimulator expression, and immunosuppression. Finally, we direct our focus to the signaling mechanisms, evolutionary conservation aspects, expression, and potential therapeutic strategies that could be based on tetraspanins and their interacting partners.

show abstract

Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance

Cited by 9 publications

References 39 publications

Significance Aberrant Of CD133 Expression and Their Clinical Impact in Acute Lymphoblastic Leukemia among Sudanese Patients in Khartoum State

Significance Aberrant Of CD133 Expression and Their Clinical Impact in Acute Lymphoblastic Leukemia among Sudanese Patients in Khartoum State

CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/β-catenin signaling pathway

Expression and Function of Tetraspanins and Their Interacting Partners in B Cells

Contact Info

Product

Resources

About